June 10, 2012
The May 31, 2012, QuarterWatch, Monitoring FDA MedWatch Reports, released by the ISMP (Institute for Safe Medication Practices) has confirmed that PRADAXA (DABIGATRAN ETEXILATE) lead all drugs in adverse event reports in 2011 with a total of 3,781 serious adverse events reported by both the manufacturer and direct reports. More information appears here at PRADAXA CASES. 

The May 31, 2012, QuarterWatch, Monitoring FDA MedWatch Reports, released by the ISMP (Institute for Safe Medication Practices) has confirmed that PRADAXA (DABIGATRAN ETEXILATE) lead all drugs in adverse event reports in 2011 with a total of 3,781 serious adverse events reported by both the manufacturer and direct reports. More information appears here at PRADAXA CASES. 

3:10pm  |   URL: http://tmblr.co/ZVGAkvN7zYQf
Filed under: PRADAXA DABIGATRAN PRADAXA DOSING PRADAXA SIDE EFFECTS PRADAXA LAWSUITS PRADAXA LAWYERS PRADAXA DEATHS PRADAXA STROKES PRADAXA LIVER FAILURE PRADAXA BLEEDING PRADAXA HEMORRHAGE PRADAXA ACUTE CORONARY SYNDROME PRADAXA HEART ATTACKS ISMP INSTITUTE SAFE MEDICATION PRACTICES FDA FOOD DRUG ADMINISTRATION PRADAXA MEDWATCH PRADAXA SAFETY SIGNALS PRADAXA QUARTERWATCH PRADAXA ADVERSE EVENT REPORTS DABIGATRAN LAWSUITS DABIGATRAN LAWYERS DABIGATRAN DOSING DABIGATRAN DEATHS DABIGATRAN BLEEDING DABIGATRAN STROKES 
Liked posts on Tumblr: More liked posts »